Paul G. Allen Frontiers Group [to 26 Oct 2019]
No new digest content identified.


BMGF – Gates Foundation [to 26 Oct 2019]
No new digest content identified.


Bill & Melinda Gates Medical Research Institute [to 26 Oct 2019]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.


CARB-X [to 26 Oct 2019]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.


CEPI – Coalition for Epidemic Preparedness Innovations [to 26 Oct 2019]
No new digest content identified.


Clinton Health Access Initiative, Inc. (CHAI) [to 26 Oct 2019]
News & Press Releases
No new digest content identified.


EDCTP [to 26 Oct 2019]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.


Emory Vaccine Center [to 26 Oct 2019]
No new digest content identified.


European Medicines Agency [to 26 Oct 2019]
News & Press Releases
News: Dialogue with Chinese authorities on medicine regulation
Last updated: 25/10/2019
… China is one of the main suppliers of active pharmaceutical ingredients to the EU and constitutes one of the world’s largest national pharmaceutical markets.


European Vaccine Initiative [to 26 Oct 2019]
No new digest content identified.


FDA [to 26 Oct 2019]
Press Announcements
No new digest content identified.


Fondation Merieux [to 26 Oct 2019]
News, Events
Over 2,300 students and professionals enrolled in the Mérieux Foundation’s first MOOC on quality management
October 24, 2019 – Lyon (France)
The Mérieux Foundation is launching a MOOC – Massive Open Online Course – on quality management in clinical laboratories. The course, which is open to all, teaches about the implementation of quality management systems.


Gavi [to 26 Oct 2019]
Latest news
Gavi celebrates global eradication of wild poliovirus type 3  
Certification officially announced at World Polio Day event in Geneva
Geneva, 24 October 2019 – Gavi, the Vaccine Alliance has welcomed the announcement today by an independent commission of experts that wild poliovirus type 3 (WPV3) has been eradicated worldwide. The official announcement was made at a World Polio Day event organised by WHO in Geneva.
WPV3 is the second of three strains of wild poliovirus to have been certified eradicated. Wild poliovirus type 2 (WPV2) was confirmed eradicated in 2015 and wild poliovirus type 1 (WPV1) remains in circulation in areas of Pakistan and Afghanistan.
“This announcement represents a tremendous victory in the fight against polio.” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. “It is a testament to decades of effort by hundreds of thousands of vaccinators and health care workers as well as WHO and its partners – and it is a reminder of the real strides we can make with focused commitment and collaboration. Harnessing this momentum and remaining vigilant will be critical as we continue to work towards a polio-free world.”…


GHIT Fund [to 26 Oct 2019]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.


Global Fund [to 26 Oct 2019]
News & Stories
Technical Review Panel Observations on the 2017-2019 Allocation Cycle
24 October 2019
… Charged with evaluating funding requests for strategic focus, technical soundness and potential for impact, the Technical Review Panel reviewed each of the 225 applications in 2017-2019. At the request of the Strategy Committee of the Global Fund Board, the Technical Review Panel reflected upon these funding requests, identifying key trends, lessons learned, and recommendations for each of the diseases and for resilient and sustainable systems for health.
The panel’s recommendations include:
:: Improving the setting of priorities
:: Increasing the focus on prevention and reducing incidence
:: Strengthening cross-cutting programming in resilient and sustainable systems for health
:: Strengthening community systems
:: Increasing attention to sustainability and transition
The Technical Review Panel advises that their recommendations be considered as countries develop their funding requests for 2020-2022:
Technical Review Panel’s Observations on the 2017-2019 Allocation Cycle
download in

World Bank and Global Fund Deepen Partnership with Co-Financing Agreement
22 October 2019
WASHINGTON – The World Bank and the Global Fund have signed a co-financing framework agreement to accelerate efforts by countries to end HIV, tuberculosis and malaria and build sustainable systems for health.
The framework agreement outlines a new approach for joint financing of investment-type operations between the two organizations, as well as results-based financing.
In recent years, the Global Fund and the World Bank have signed multiple innovative finance agreements, such as a loan buy-down for a program to fight tuberculosis in India, a performance-based funding project in the Democratic Republic of Congo and a Multi-Donor Trust Fund for Indonesia and Sri Lanka. The framework agreement is expected to reduce transaction costs and lays the foundation for a deeper partnership with the aim of increasing impact.
“Partnership is in the Global Fund’s DNA, and our work with partners such as the World Bank will accelerate the fight to end the epidemics,” said Peter Sands, Executive Director of the Global Fund. “Innovative financing mechanisms can play a significant role in improving the effectiveness of our investments and in pursuing new financial opportunities to increase impact.”…


Hilleman Laboratories [to 26 Oct 2019]
No new digest content identified.


Human Vaccines Project [to 26 Oct 2019]
Press Releases
No new digest content identified.


IAVI [to 26 Oct 2019]
No new digest content identified.



International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.



International Generic and Biosimilar Medicines Association [IGBA]
No new digest content identified.



No new digest content identified.


IFRC [to 26 Oct 2019]
Selected Press Releases, Announcements
Asia Pacific
Philippines: Red Cross triples polio vaccination target
The Philippine Red Cross is more than tripling the number of children it aims to vaccinate in a door-to-door polio vaccination campaign, the Red Cross and the International Federation of Red Cross and Red Crescent Societies (IFRC) said today.
25 October 2019
[See Polio above for detail]


IVAC [to 26 Oct 2019]
No new digest content identified.


IVI [to 26 Oct 2019]
Selected IVI News & Announcements
No new digest content identified.


JEE Alliance [to 26 Oct 2019]
Selected News and Events
No new digest content identified.


MSF/Médecins Sans Frontières [to 26 Oct 2019]
Latest [Selected Announcements]
Northeast Nigeria: Now is not the time to question lifesaving as…
Statement 25 Oct 2019
Serious medical needs remain widespread in northeast Nigeria, while essential items and clean drinking water are scarce; in the first half of 2019 alone, our teams admitted more than 15,000 patients on an emergency basis, treated over 8,000 patients for malaria, ensured 2,446 safe deliveries and vaccinated 9,117 people against measles

MSF providing medical care in Iraq to people fleeing northeast Syria
Statement 21 Oct 2019


National Vaccine Program Office – U.S. HHS [to 26 Oct 2019]
No new digest content identified.


NIH [to 26 Oct 2019]
Selected News Releases
Broadly protective antibodies could lead to better flu treatments and vaccines
October 25, 2019 — Isolated antibodies provided broad protection against several different strains of influenza.

Ending HIV will require optimizing treatment and prevention tools, say NIH experts
October 24, 2019 — Commentary emphasizes need to optimally implement current tools and develop new interventions.

Influenza human challenge study begins at NIH-sponsored clinical trial units
October 23, 2019 — Up to 80 people aged 18 to 50 years will be enrolled in the trial.
A clinical trial in which healthy adults will be deliberately infected with influenza virus under carefully controlled conditions is recruiting volunteers at four Vaccine and Treatment Evaluation Units (VTEUs) supported by the National Institute of Allergy and Infectious Diseases (NIAID). One study aim is to assess how levels of pre-existing influenza antibodies impact the timing, magnitude and duration of a volunteer’s flu symptoms following exposure to influenza virus. NIAID is part of the National Institutes of Health.

NIH launches new collaboration to develop gene-based cures for sickle cell disease and HIV on global scale
October 23, 2019 — Initial investment aims to advance accessible and scalable candidate interventions into clinical trials within 10 years.
[See Perspectives above for detail]


PATH [to 26 Oct 2019]
Selected Announcements
No new digest content identified.


Sabin Vaccine Institute [to 26 Oct 2019]
Statements and Press Releases
October 24, 2019
One Step Closer to a World Without Polio – Type 3 Polio Eradicated – A Statement by the Sabin Vaccine Institute
WASHINGTON, DC – Today, we are one step closer to a world without polio. The Sabin Vaccine Institute, founded in memory of oral polio vaccine creator Dr. Albert Sabin, applauds the tremendous achievement by the global polio community in eradicating wild poliovirus type 3.
…“At a time when the wins are hard-fought and far-between, the eradication of wild poliovirus type 3 is a much-needed reminder that just as the global community coalesced to eradicate smallpox, we can and we will make polio history,” said Dr. Bruce Gellin, president of Global Immunization at the Sabin Vaccine Institute. “We have come this far thanks parents and caregivers who ensure that their children are protected and to the unflagging efforts of organizers, advocates and the brave individuals who put themselves in harm’s way to ensure every child is protected from this deadly disease. But as we celebrate this accomplishment, we must remember that progress against wild poliovirus type 1 is precarious. Now, more than ever, we must recommit to realizing Dr. Sabin’s vision of a world without polio.”


UNAIDS [to 26 Oct 2019]
Selected Press Releases/Reports/Statements
21 October 2019
Voluntary medical male circumcision―4.1 million performed in 2018
…About 11 million VMMCs have been performed in 15 priority countries in eastern and southern Africa since the beginning of 2016. In 2018 alone, about 4.1 million voluntary circumcisions were performed among males of all ages, a slight increase from the 4 million carried out in 2017.
There has been progress towards the target of 25 million additional circumcisions for HIV prevention from 2016 to 2020. However, at the end of 2018, when 15 million circumcisions should have been performed, the world was off-target by 4 million circumcisions…

21 October 2019
Educational show on how to talk with teenagers about health and sexual relations


UNICEF [to 26 Oct 2019]
Selected Statements, Press Releases, Reports
Press release
UNICEF and partners provide vaccination against polio and measles for nearly 232,000 children in Syria and Iraq, many affected by violence in northeast Syria
[See Emergencies above for detail]

Press release
UNICEF update on the humanitarian situation for children in north east Syria
DAMASCUS/AMMAN/GENEVA/NEW YORK, 22 October 2019 – The latest estimates put the number of children displaced since 9 October at 80,000. Five children have been killed and 26 injured…
UNICEF teams are at the border, working with partners and the Directorate of Health, to provide water, ready to eat food, and hygiene kits, and vaccinate children against polio and measles. A mobile child protection team is also at the Sahela border, providing psychosocial support and responding to urgent cases. So far, nine unaccompanied children have been identified, six of whom have been reunited with families; two whose families have been traced, and one whose case is still being followed up. At Badarash camp, UNICEF is also vaccinating children, providing psychosocial support, and working to identify and refer children and women who require specialized assistance.

Press release
Lack of funding leaves millions of children in conflict and disaster zones at risk
$4 billion humanitarian appeal nearly 50 per cent unfunded heading into final quarter of 2019


Vaccination Acceptance Research Network (VARN) [to 26 Oct 2019]
No new digest content identified.


Vaccine Confidence Project [to 26 Oct 2019]
No new digest content identified.


Vaccine Education Center – Children’s Hospital of Philadelphia [to 26 Oct 2019]
No new digest content identified.


Wellcome Trust [to 26 Oct 2019]
Opinion | 24 October 2019
Leaving academia: there are still opportunities to make a difference in research
Danil Mikhailov, Head of Wellcome Data Labs Wellcome
Leaving academia isn’t the same as leaving research, which is why we need to reimagine what a successful research career looks like.

Opinion | 22 October 2019
What accountability means to Wellcome
Mark Henderson, Director of Communications Wellcome
Philanthropic foundations aren’t answerable to taxpayers, shareholders or politicians. So what is their social value? For the past 18 months, we have been thinking about Wellcome’s social value – and what it means for our purpose and mission.


Why We Vaccinate [to 26 Oct 2019]
No new digest content identified.


The Wistar Institute [to 26 Oct 2019]
Press Release Oct. 22, 2019
Wistar Institute Researcher Awarded American Cancer Society Research Professorship
PRINCETON, N.J. — PHILADELPHIA — (Oct. 22, 2019) — The American Cancer Society (ACS), the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded a Research Professorship to Dmitry l. Gabrilovich, M.D., Ph.D., Christopher M. Davis Professor and leader of the Immunology, Microenvironment & Metastasis Program at The Wistar Institute. This lifelong designation, accompanied by a five-year $400,000 commitment, is the most prestigious research grant made by ACS.


World Organisation for Animal Health (OIE) [to 26 Oct 2019]
No new digest content identified.





ARM [Alliance for Regenerative Medicine] [to 26 Oct 2019]
October 10, 2019
Gene Therapies: Sector Overview, New York Academy of Sciences Workshop
New York City


BIO [to 26 Oct 2019]
Oct 22 2019
America’s Bioeconomy Plays Critical Role in Feeding, Fueling, and Healing the World
“What has set the U.S. biotech sector apart has been thoughtful, bipartisan public policy approaches that create a favorable climate in which to undertake the lengthy and risky job of investing in and developing the next biotech breakthroughs.”


DCVMN – Developing Country Vaccine Manufacturers Network [to 26 Oct 2019]
No new digest content identified.


IFPMA [to 26 Oct 2019]
Selected Press Releases, Statements, Publications
Global Health Progress launched to drive cross-sectoral collaborations in support of the Sustainable Development Goals
25 October 2019
Global Health Progress is a new knowledge hub highlighting over 200 collaborations between the innovative biopharmaceutical industry and more than 850 partners to support the SDGs. Users can explore collaborations by SDG target, disease area, program strategy, and more. Users are also encouraged to connect with partners via the platform to drive new collaborations in low- and middle-income countries.


PhRMA [to 26 Oct 2019]
Selected Press Releases, Statements
No new digest content identified.


Industry Watch [to 26 Oct 2019]
:: GSK agrees to divest rabies and tick-borne encephalitis vaccines to Bavarian Nordic
GSK to receive upfront payment of approximately EUR301 million (£259m) and milestone payments for a total consideration of up to EUR955 million (£822m)
21 October 2019 Issued: London, UK
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the divestment of travel vaccines Rabipur (tradename Rabavert in the US) for the prevention of rabies, and Encepur for the prevention of tick-borne encephalitis, to Bavarian Nordic.
The decision to divest these brands, acquired from Novartis in 2015 as part of the acquisition of its vaccines business, supports GSK’s strategic intent to increase focus and reinvest in growth assets, innovation and a simplified supply chain in its vaccines business…